Abiopharma

🔍 Grossman Adam S (Executive)

Company: ADMA BIOLOGICS, INC. (ADMA)

Report Date: 2026-03-16

Detailed Transactions and Holdings:

• Acquired 15,000 shares of Common Stock at $5.4 per share (Direct)
  Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,133,777.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 15,000 shares of Common Stock at $15.16 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,118,777.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 6,000 shares of Common Stock at $15.16 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,112,777.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-16 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,143,426.00 | Footnotes: F6
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-16 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 580,957.00 | Footnotes: F7
• Sold 15,000 shares of Stock Option (right to buy) at $5.4 per share (Derivative)
  Date: 2026-03-16 | Code: M | Expires: 2034-02-26 | equity_swap_involved: 0 | shares_owned_after: 690,950.00 | transaction_form_type: 4 | Footnotes: F1, F8

Footnotes:

• F1: Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
• F2: The price reported in Column 4 is the price at which the shares were sold.
• F3: Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
• F4: (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
• F5: (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
• F6: These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
• F7: These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
• F8: The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.